[January 27, 2015]

MetaStat Enters into Agreement to Access Tumor Samples and Clinical Data from Kaiser Foundation Hospitals

MetaStat, Inc. (OTCQB: MTST), a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, has executed a material/data transfer agreement with Kaiser Foundation Hospitals. Under the terms of the agreement, MetaStat will receive de-identified tissue samples, clinical data and medical histories for up to 500 patients with or without metastatic breast cancer for testing using the Company's MetaSite Breast™ and MenaCalc Breast™ diagnostic assays for the early and reliable prediction of systemic metastasis.

"These tissues samples will allow us to independently verify and validate results from the recently published study¹ on the prediction of distant metastasis of breast cancer by Rohan et al. in the Journal of the National Cancer Institute," said Oscar Bronsther, M.D., MetaStat's Chief Executive Officer and Chief Medical Officer. "We look forward to initiating our validation study using the Kaiser tissue samples later this month and reporting these data to the medical community later this year."

About Kaiser Permanente

Kaiser Permanente is recognized as one of America's leading health care providers and nonprofit health plans. Founded in 1945, its mission is to provide high-quality, affordable health care services to its members and communities. Kaiser Permanente currently serves approximately 9.5 million members in eight states and the District of Colubia.

About MetaStat, Inc.

MetaStat, Inc. (MTST) is a molecular diagnostic company that develops and commercializes diagnostic tests for early and reliable prediction of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The company's function-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ assays are designed to accurately stratify patients based on their individual risk of metastasis and to provide physicians with clinically actionable information to better "customize" cancer treatment. MetaStat's testing platform improves treatment planning decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. The company is based in Boston.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.

1. Rohan TE, XueX, Lin HM, et al. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. J Natl Cancer Inst. 2014 June 3;106(8). pii: dju136. doi: 10.1093/jnci/dju136. Print 2014 Aug.

[ Back To TMCnet.com's Homepage ]